Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Platinum-based chemotherapy is the standard of care for patients with advanced non-small cell lung cancer, but clinical challenges remain in determining safe and effective treatments for elderly patients and those with performance status 2, who may not be able to tolerate standard regimens. Because carboplatin is associated with a better tolerability profile than cisplatin, with comparable efficacy, carboplatin-based combination regimens are the "community standard of care". The standard of care appropriate for elderly and performance status 2 patients, however, remains controversial. Under-representation of elderly and performance status 2 patients in clinical trials and fears about the suitability of treating such patients with the same therapies as those used in younger and healthier patients, hinders evidence-based decisions regarding care. Recent evidence indicates that "fit" elderly patients respond to platinum-based doublet therapy with reasonable tolerability. Particularly in the presence of substantial comorbidities, patients with poor performance status are less responsive to chemotherapy than healthier patients. However, the decision to proceed with treatment may be appropriate for selected patients. In clinical trials with performance status 2 patients, greater clinical efficacy was seen with carboplatin-based doublets than single-agent paclitaxel, suggesting that carboplatin-based doublets can be effective treatment in this population. Optimal carboplatin administration in combination with paclitaxel is yet to be determined, but phase II trials indicate that weekly paclitaxel plus monthly full-dose carboplatin may offer enhanced tolerability and efficacy versus standard every-3-week schedules. A phase III trial comparing these schedules has been completed and will be reported in 2004.

Original languageEnglish (US)
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume2 Suppl 2
StatePublished - Jan 1 2004

Fingerprint

Platinum
Drug Therapy
Carboplatin
Population
Standard of Care
Paclitaxel
Appointments and Schedules
Clinical Trials
Therapeutics
Non-Small Cell Lung Carcinoma
Cisplatin
Fear
Comorbidity

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{976da9dfe4ec47b18acf25919b252650,
title = "Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations.",
abstract = "Platinum-based chemotherapy is the standard of care for patients with advanced non-small cell lung cancer, but clinical challenges remain in determining safe and effective treatments for elderly patients and those with performance status 2, who may not be able to tolerate standard regimens. Because carboplatin is associated with a better tolerability profile than cisplatin, with comparable efficacy, carboplatin-based combination regimens are the {"}community standard of care{"}. The standard of care appropriate for elderly and performance status 2 patients, however, remains controversial. Under-representation of elderly and performance status 2 patients in clinical trials and fears about the suitability of treating such patients with the same therapies as those used in younger and healthier patients, hinders evidence-based decisions regarding care. Recent evidence indicates that {"}fit{"} elderly patients respond to platinum-based doublet therapy with reasonable tolerability. Particularly in the presence of substantial comorbidities, patients with poor performance status are less responsive to chemotherapy than healthier patients. However, the decision to proceed with treatment may be appropriate for selected patients. In clinical trials with performance status 2 patients, greater clinical efficacy was seen with carboplatin-based doublets than single-agent paclitaxel, suggesting that carboplatin-based doublets can be effective treatment in this population. Optimal carboplatin administration in combination with paclitaxel is yet to be determined, but phase II trials indicate that weekly paclitaxel plus monthly full-dose carboplatin may offer enhanced tolerability and efficacy versus standard every-3-week schedules. A phase III trial comparing these schedules has been completed and will be reported in 2004.",
author = "Chandra Belani",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
volume = "2 Suppl 2",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",

}

TY - JOUR

T1 - Challenges in advanced NSCLC

T2 - optimizing platinum-based chemotherapy and treating special populations.

AU - Belani, Chandra

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Platinum-based chemotherapy is the standard of care for patients with advanced non-small cell lung cancer, but clinical challenges remain in determining safe and effective treatments for elderly patients and those with performance status 2, who may not be able to tolerate standard regimens. Because carboplatin is associated with a better tolerability profile than cisplatin, with comparable efficacy, carboplatin-based combination regimens are the "community standard of care". The standard of care appropriate for elderly and performance status 2 patients, however, remains controversial. Under-representation of elderly and performance status 2 patients in clinical trials and fears about the suitability of treating such patients with the same therapies as those used in younger and healthier patients, hinders evidence-based decisions regarding care. Recent evidence indicates that "fit" elderly patients respond to platinum-based doublet therapy with reasonable tolerability. Particularly in the presence of substantial comorbidities, patients with poor performance status are less responsive to chemotherapy than healthier patients. However, the decision to proceed with treatment may be appropriate for selected patients. In clinical trials with performance status 2 patients, greater clinical efficacy was seen with carboplatin-based doublets than single-agent paclitaxel, suggesting that carboplatin-based doublets can be effective treatment in this population. Optimal carboplatin administration in combination with paclitaxel is yet to be determined, but phase II trials indicate that weekly paclitaxel plus monthly full-dose carboplatin may offer enhanced tolerability and efficacy versus standard every-3-week schedules. A phase III trial comparing these schedules has been completed and will be reported in 2004.

AB - Platinum-based chemotherapy is the standard of care for patients with advanced non-small cell lung cancer, but clinical challenges remain in determining safe and effective treatments for elderly patients and those with performance status 2, who may not be able to tolerate standard regimens. Because carboplatin is associated with a better tolerability profile than cisplatin, with comparable efficacy, carboplatin-based combination regimens are the "community standard of care". The standard of care appropriate for elderly and performance status 2 patients, however, remains controversial. Under-representation of elderly and performance status 2 patients in clinical trials and fears about the suitability of treating such patients with the same therapies as those used in younger and healthier patients, hinders evidence-based decisions regarding care. Recent evidence indicates that "fit" elderly patients respond to platinum-based doublet therapy with reasonable tolerability. Particularly in the presence of substantial comorbidities, patients with poor performance status are less responsive to chemotherapy than healthier patients. However, the decision to proceed with treatment may be appropriate for selected patients. In clinical trials with performance status 2 patients, greater clinical efficacy was seen with carboplatin-based doublets than single-agent paclitaxel, suggesting that carboplatin-based doublets can be effective treatment in this population. Optimal carboplatin administration in combination with paclitaxel is yet to be determined, but phase II trials indicate that weekly paclitaxel plus monthly full-dose carboplatin may offer enhanced tolerability and efficacy versus standard every-3-week schedules. A phase III trial comparing these schedules has been completed and will be reported in 2004.

UR - http://www.scopus.com/inward/record.url?scp=73349117529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349117529&partnerID=8YFLogxK

M3 - Review article

C2 - 19780242

AN - SCOPUS:73349117529

VL - 2 Suppl 2

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

ER -